Digest Network Come funziona
Network
/
Società
Sh
Non verificato

Shionogi Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteScienza

7 comunicati stampa

Guarda tutti i comunicati
26/10/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Shionogi to Present New Real-World Data Advancing the Understanding of ALS at the 2026 Annual NEALS Meeting
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0
21/10/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Eventi
Fiere
Industria
IDWeek 2026: New Exploratory Analyses Evaluate XOCOVA® (ensitrelvir) Following COVID-19 Exposure, Including Breakthrough Infections and Infection Present at Baseline
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0
21/10/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Cardiologia
Biotecnologia
Salute
Farmaceutica
Eventi
Industria
IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0
05/10/2026
Mercato azionario
Scienza
HIV, AIDS e malattie autoimmuni
Cardiologia
Sanità
Biotecnologia
Farmaceutica
Salute
Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0
09/09/2026
Eventi
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Igiene alimentare
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Shionogi to Showcase Advancements Across its Infectious Disease Portfolio at IDWeek 2026
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0
28/07/2026
Shionogi Announces U.S. Availability of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure*
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0
16/07/2026
Scienza
Attrezzature medico-sanitarie
HIV, AIDS e malattie autoimmuni
Infanzia
Igiene alimentare
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Industria
FDA Accepts Shionogi’s sNDA for Fetroja® (cefiderocol) for Use in Pediatric Patients with Serious Infections Caused by Susceptible Gram-negative Bacteria
Fonte
Shionogi Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0